Alzheimer disease: Progress or profit?
Article Abstract:
The challenge to develop targeted, effective treatments, recognize early symptoms and intervene to prevent disease progression have become more crucial as population demographics shift and the number of individuals with Alzheimer disease continues to increase. Clinical developments in this field is complex, expensive and uncertain in terms of predicting success, but there are considerable opportunities in the Alzheimer disease market and disease-modifying drugs have the potential to expand it further.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Can the immune system fight Alzheimer disease?
Article Abstract:
The AN1792 clinical trial of A(beta) immunization was carried out in individuals with Alzheimer disease in a randomized multicenter placebo-controlled double-blind study. Those who received active treatment had a small but statistically significant improvement on memory measures, based on a composite score of several neuropsychological tests while the indices of brain atrophy were significantly greater in individuals treated with AN1792 who had an antibody response than the placebo group.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2006
User Contributions:
Comment about this article or add new information about this topic: